MorphoSys AG reiterated Monjuvi U.S. net product sales guidance for the year 2022. Monjuvi U.S. Net Product Sales expects to be USD 110 million to USD 135 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.6 EUR | +0.15% | +0.90% | +98.82% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+98.82% | 2.72B | |
+23.13% | 52.73B | |
+37.49% | 39B | |
-8.73% | 38.52B | |
+28.09% | 30.38B | |
-12.26% | 26.39B | |
+10.57% | 26.08B | |
+45.05% | 14.15B | |
+32.23% | 12.6B | |
-6.56% | 11.51B |
- Stock Market
- Equities
- MOR Stock
- News MorphoSys AG
- MorphoSys AG Reiterates Monjuvi U.S. Net Product Sales Guidance for the Year 2022